IL302997B1 - Purine inhibitors - Google Patents
Purine inhibitorsInfo
- Publication number
- IL302997B1 IL302997B1 IL302997A IL30299723A IL302997B1 IL 302997 B1 IL302997 B1 IL 302997B1 IL 302997 A IL302997 A IL 302997A IL 30299723 A IL30299723 A IL 30299723A IL 302997 B1 IL302997 B1 IL 302997B1
- Authority
- IL
- Israel
- Prior art keywords
- alkyl
- formula
- independently selected
- compound
- salt
- Prior art date
Links
- 102000004961 Furin Human genes 0.000 title 1
- 108090001126 Furin Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 92
- 150000001875 compounds Chemical class 0.000 claims 40
- 150000003839 salts Chemical class 0.000 claims 35
- 125000005843 halogen group Chemical group 0.000 claims 28
- 229910052736 halogen Inorganic materials 0.000 claims 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 24
- 229910052757 nitrogen Inorganic materials 0.000 claims 23
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 20
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 19
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- 239000001257 hydrogen Substances 0.000 claims 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 17
- 125000004043 oxo group Chemical group O=* 0.000 claims 17
- 125000001424 substituent group Chemical group 0.000 claims 17
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 14
- 125000002950 monocyclic group Chemical group 0.000 claims 13
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 13
- 229920006395 saturated elastomer Polymers 0.000 claims 13
- 239000002904 solvent Substances 0.000 claims 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 125000005842 heteroatom Chemical group 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 239000001301 oxygen Substances 0.000 claims 10
- 229910052717 sulfur Chemical group 0.000 claims 10
- 239000011593 sulfur Chemical group 0.000 claims 10
- 230000002194 synthesizing effect Effects 0.000 claims 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 7
- 239000003054 catalyst Substances 0.000 claims 7
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 7
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 7
- 229910052751 metal Inorganic materials 0.000 claims 7
- 239000002184 metal Substances 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 125000003831 tetrazolyl group Chemical group 0.000 claims 7
- 125000001425 triazolyl group Chemical group 0.000 claims 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 7
- 239000002253 acid Substances 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 4
- 229910052763 palladium Inorganic materials 0.000 claims 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 3
- 150000004678 hydrides Chemical class 0.000 claims 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 claims 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims 2
- 150000007524 organic acids Chemical class 0.000 claims 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical group [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 claims 1
- 229910002666 PdCl2 Inorganic materials 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 150000007529 inorganic bases Chemical class 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical group Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 claims 1
- 229910000033 sodium borohydride Inorganic materials 0.000 claims 1
- 239000012279 sodium borohydride Substances 0.000 claims 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862670050P | 2018-05-11 | 2018-05-11 | |
| PCT/EP2019/062098 WO2019215341A1 (en) | 2018-05-11 | 2019-05-10 | Furin inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL302997A IL302997A (en) | 2023-07-01 |
| IL302997B1 true IL302997B1 (en) | 2024-04-01 |
Family
ID=66597541
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL302997A IL302997B1 (en) | 2018-05-11 | 2019-05-10 | Purine inhibitors |
| IL278642A IL278642B2 (en) | 2018-05-11 | 2019-05-10 | Purine inhibitors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL278642A IL278642B2 (en) | 2018-05-11 | 2019-05-10 | Purine inhibitors |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11773078B2 (zh) |
| EP (1) | EP3790871B1 (zh) |
| JP (1) | JP7350061B2 (zh) |
| KR (1) | KR20210021298A (zh) |
| CN (1) | CN112384509B (zh) |
| AU (1) | AU2019267166C1 (zh) |
| BR (1) | BR112020022961A2 (zh) |
| CA (1) | CA3099863A1 (zh) |
| IL (2) | IL302997B1 (zh) |
| MX (1) | MX2020012034A (zh) |
| SG (1) | SG11202010914YA (zh) |
| WO (1) | WO2019215341A1 (zh) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11773078B2 (en) | 2018-05-11 | 2023-10-03 | Glaxosmithkline Intellectual Property Development Limited | Furin inhibitors |
| US20230011571A1 (en) * | 2019-11-12 | 2023-01-12 | Bp Asset V, Inc. | Small molecule furin inhibitors for treating infectious diseases |
| WO2021097008A1 (en) * | 2019-11-12 | 2021-05-20 | Bp Asset V, Inc. | Use of pyridyloxypyridines for treating infectious diseases |
| WO2021097002A1 (en) * | 2019-11-12 | 2021-05-20 | Bp Asset V, Inc. | Use of pyridyloxypyrimidines for treating infectious diseases |
| KR20220167296A (ko) | 2020-04-02 | 2022-12-20 | 비피 애셋 브이, 인크. | 코로나바이러스 감염을 치료하기 위한 푸린 억제제 |
| FR3110345B1 (fr) | 2020-05-21 | 2024-03-29 | Agence Francaise Pour Le Dev D’Al Ula | Hydrolysat de protéines du tourteau des graines de Moringa peregrina pour son application en tant que médicament, son procédé d’obtention et compositions pharmaceutiques, dermatologiques et cosmétiques. |
| AU2022215580A1 (en) | 2021-02-03 | 2023-08-10 | Bp Asset V, Inc. | Formulation of furin inhibitor for inhalation |
| CN114853640A (zh) * | 2022-05-12 | 2022-08-05 | 马鞍山昂扬新材料科技有限公司 | 2-溴乙基磺酸钠的制备方法 |
| WO2024073576A1 (en) * | 2022-09-29 | 2024-04-04 | Bp Asset V, Inc. | 4-((2-(3,5-dichlorophenyl)-6-((pyrimidin-5-yl)oxy)pyridin-4-yl)methyl)piperazine derivatives as furin inhibitors and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ535425A (en) | 2002-03-13 | 2008-05-30 | Biogen Idec Inc | Anti-alphavbeta6 antibodies |
| KR101052482B1 (ko) | 2002-11-21 | 2011-07-28 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 포스포티딜이노시톨(ｐｉ) 3-키나제 억제제인 2,4,6-삼치환피리미딘 및 암의 치료에서 이들의 사용 |
| WO2005047268A2 (en) | 2003-11-10 | 2005-05-26 | X-Ceptor Therapeutics, Inc. | Substituted pyrimidine compositions and methods of use |
| CA2586086A1 (en) | 2004-07-23 | 2006-01-23 | Robert E.(Deceased) Smith | Furin inhibitors |
| CA2579143A1 (en) * | 2004-09-13 | 2006-03-23 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| EP2155894A4 (en) | 2007-05-09 | 2010-08-18 | Burnham Inst Medical Research | HOST PROTEINAS AS A TARGET FOR A THERAPEUTIC STRATEGY AGAINST VIRAL AND BACTERIAL DISEASES |
| JP5328816B2 (ja) | 2008-02-22 | 2013-10-30 | エフ．ホフマン−ラ ロシュ アーゲー | アミロイドβの調節薬 |
| NO2629776T3 (zh) | 2010-10-18 | 2018-01-13 | ||
| US9266828B2 (en) | 2012-03-16 | 2016-02-23 | Sanford-Burnham Medical Research Institute | Inhibitors of Furin and other pro-protein convertases |
| WO2013138666A1 (en) | 2012-03-16 | 2013-09-19 | Sanford-Burnham Medical Research Institute | Inhibitors of furin and other pro-protein convertases |
| EP2884982B1 (en) | 2012-08-20 | 2017-09-20 | Merck Sharp & Dohme Corp. | SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| US10150742B2 (en) | 2013-03-15 | 2018-12-11 | President And Fellows Of Harvard College | Substituted heterocyclic compounds for treating or preventing viral infections |
| EP3265445B1 (en) | 2015-03-06 | 2021-05-05 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
| CN107441094B (zh) | 2017-08-08 | 2020-05-22 | 南方医科大学 | 尼罗替尼作为治疗登革病毒感染的药物及其制药用途 |
| US11773078B2 (en) | 2018-05-11 | 2023-10-03 | Glaxosmithkline Intellectual Property Development Limited | Furin inhibitors |
| US20230011571A1 (en) | 2019-11-12 | 2023-01-12 | Bp Asset V, Inc. | Small molecule furin inhibitors for treating infectious diseases |
-
2019
- 2019-05-10 US US17/054,491 patent/US11773078B2/en active Active
- 2019-05-10 AU AU2019267166A patent/AU2019267166C1/en active Active
- 2019-05-10 JP JP2021513005A patent/JP7350061B2/ja active Active
- 2019-05-10 KR KR1020207035245A patent/KR20210021298A/ko unknown
- 2019-05-10 IL IL302997A patent/IL302997B1/en unknown
- 2019-05-10 BR BR112020022961-0A patent/BR112020022961A2/pt unknown
- 2019-05-10 MX MX2020012034A patent/MX2020012034A/es unknown
- 2019-05-10 SG SG11202010914YA patent/SG11202010914YA/en unknown
- 2019-05-10 CN CN201980046497.1A patent/CN112384509B/zh active Active
- 2019-05-10 IL IL278642A patent/IL278642B2/en unknown
- 2019-05-10 CA CA3099863A patent/CA3099863A1/en active Pending
- 2019-05-10 EP EP19725058.2A patent/EP3790871B1/en active Active
- 2019-05-10 WO PCT/EP2019/062098 patent/WO2019215341A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN112384509A (zh) | 2021-02-19 |
| SG11202010914YA (en) | 2020-12-30 |
| EP3790871B1 (en) | 2024-01-24 |
| JP2021523941A (ja) | 2021-09-09 |
| BR112020022961A2 (pt) | 2021-02-17 |
| AU2019267166C1 (en) | 2023-11-30 |
| IL278642B2 (en) | 2023-10-01 |
| KR20210021298A (ko) | 2021-02-25 |
| AU2019267166B2 (en) | 2023-06-15 |
| AU2019267166A1 (en) | 2020-11-26 |
| IL278642A (zh) | 2020-12-31 |
| WO2019215341A1 (en) | 2019-11-14 |
| US20220315556A1 (en) | 2022-10-06 |
| EP3790871C0 (en) | 2024-01-24 |
| US11773078B2 (en) | 2023-10-03 |
| CN112384509B (zh) | 2024-04-30 |
| IL302997A (en) | 2023-07-01 |
| IL278642B1 (en) | 2023-06-01 |
| MX2020012034A (es) | 2021-04-12 |
| EP3790871A1 (en) | 2021-03-17 |
| CA3099863A1 (en) | 2019-11-14 |
| JP7350061B2 (ja) | 2023-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL302997B1 (en) | Purine inhibitors | |
| JP5559745B2 (ja) | ２−ピリジルエチルカルボキサミド誘導体の調製方法 | |
| JP2017507982A (ja) | ２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−１−（５−置換−ピリジン−２−イル）−３−（１ｈ−テトラゾール−１−イル）プロパン−２−オールおよびその調製工程 | |
| JP6396462B2 (ja) | フラン−２，５−ジメタノールおよび（テトラヒドロフラン−２，５−ジイル）ジメタノールのモノおよびジアルキルエーテルならびにその両親媒性誘導体 | |
| KR20180005248A (ko) | 복소환형 화합물의 합성 | |
| KR20160130813A (ko) | 프로펠란 유도체 및 합성 | |
| UA109883C2 (uk) | Спосіб отримання сполук для застосування як інгібіторів sglt2 | |
| JP2012511574A (ja) | カルバモイルピリドンｈｉｖインテグラーゼ阻害剤の製造方法および中間体 | |
| US20160355500A1 (en) | Intermediate compounds and process for the preparation of efinaconazole | |
| TW200604185A (en) | Chemical compounds | |
| RU2016138800A (ru) | Новый способ получения производных триазина, пиримидина и пиридина | |
| CN102120734A (zh) | 激活醇作为烷基化试剂制备2-(n-烷基)氨基苯并噻唑衍生物的方法 | |
| WO2004013103A3 (en) | Process for preparing quinolone antibiotic intermediates | |
| MXPA02012884A (es) | Nuevo procedimiento para la preparacion de pirazolopirimidinonas. | |
| ES2702193T3 (es) | Proceso para la preparación de compuestos de isoxazolina ópticamente activos | |
| WO2014154908A1 (en) | Selective alkylation of cyclopentyl alcohols | |
| WO2020094434A1 (en) | Process for preparation of optically enriched isoxazolines | |
| JP2013510159A (ja) | ピラジノントロンビン阻害剤およびその中間体の製造方法 | |
| WO2012005692A1 (en) | Propargylamine synthesis using a copper (i) catalysed three component coupling reaction | |
| ES2912531T3 (es) | Hidrogenación de un derivado de 2-metil cianopiridilo sustituido en presencia de un catalizador de cobalto Raney | |
| Lee et al. | Facile synthesis of Baylis-Hillman adducts bearing the carbamate or amide functional group at the secondary position | |
| WO2021205023A1 (en) | Process for the preparation of silodosin | |
| EP3448844A1 (en) | Process for the preparation of herbicidal compounds | |
| WO2008118935A1 (en) | Compounds and processes for preparing substituted aminomethyl-2,3,8,9-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-ones | |
| WO2002072540A2 (en) | Improved methods of ortho alkylation |